Freedman Financial Associates’s ResMed RMD Stock Holding History

Freedman Financial Associates’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33	Closed	-$8K	–	329
2022 Q1	$8K	Buy	+33	New	+$7.98K	0.01%	379

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Freedman Financial Associates's RMD Position: Q2 2022 in Review

Freedman Financial Associates sold out of ResMed (RMD) in Q2 2022, closing a stake of 33 shares — an estimated $8K sold.

Freedman Financial Associates first reported a position in RMD in Q1 2022 and held it in 1 quarter. The position peaked at $8K in Q1 2022. 676 funds tracked by Wall St. Rank hold RMD as of Q2 2022.

Freedman Financial Associates reported no remaining ResMed position as of Q2 2022 after selling out during the quarter.
Freedman Financial Associates sold 33 ResMed shares in Q2 2022, an estimated $8K.
Freedman Financial Associates first reported a position in ResMed in Q1 2022 and held it in 1 quarter.
Freedman Financial Associates's ResMed position peaked at $8K in Q1 2022.
676 funds tracked by Wall St. Rank held ResMed as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.